Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
9.19
-0.34 (-3.57%)
At close: Jun 5, 2025, 4:00 PM
9.19
0.00 (-0.02%)
After-hours: Jun 5, 2025, 7:48 PM EDT
Organon & Co. Employees
Organon & Co. had 10,000 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
10,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$629,400
Profits / Employee
$75,000
Market Cap
2.39B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10,000 | 0 | - |
| Dec 31, 2023 | 10,000 | 0 | - |
| Dec 31, 2022 | 10,000 | 700 | 7.53% |
| Dec 31, 2021 | 9,300 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
OGN News
- 1 day ago - OGN LAWSUIT: Organon & Co. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law - Accesswire
- 2 days ago - OGN STOCK NOTICE: Organon & Co. has been Sued for Fraud; Investors are Notified to Contact BFA Law before July 22 Legal Deadline - Accesswire
- 3 days ago - Shareholders who lost money on Organon & Co. (NYSE: OGN) Should Contact Wolf Haldenstein - PRNewsWire
- 5 days ago - OGN CLASS NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law before July 22 Court Deadline (NYSE:OGN) - GlobeNewsWire
- 6 days ago - Shareholders who lost money on Organon & Co. (NYSE: OGN). Should Contact Wolf Haldenstein - GlobeNewsWire
- 7 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN - PRNewsWire
- 9 days ago - Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Organon & Co. (OGN) - GlobeNewsWire
- 9 days ago - US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection - Business Wire